In addition to determining the direct effects of glucose on intestinal epithelial permeability, we also sought to determine if hyperglycemia-induced barrier dysfunction could be prevented with the PPARα agonist, fenofibrate, thus aiming to directly address the potential use of fenofibrate as a therapy for DM-related intestinal barrier dysfunction in feline veterinary patients while additionally supporting further investigation into the relationship between fenofibrate, diabetes, and intestinal barrier dysfunction in human patients. This evidence concerns the gene PPARA and Hyperglycemia.